RanD

What RanD does

RanD S.p.A. is a privately held Italian medical technology company founded in 1999 and headquartered in Medolla, within the Mirandola Bio-medical district. The company develops and manufactures extracorporeal circulation systems focused primarily on surgical oncology, anchored by the Performer platform. Its product portfolio comprises the Performer HT (a hyperthermic perfusion system launched in 2008), the Performer LRT (a multifunctional extracorporeal therapy system launched in 2001 spanning CRRT, plasma exchange, artificial and bio-artificial liver support, and surgical oncology), and the Performer CPB (a compact heart-lung machine developed in 2005 with Medtronic). A 2016 spin-off named Rigenerand has carried regenerative medicine work into a separate entity.

The Performer HT, RanD's flagship, supports hyperthermic intraperitoneal or intrathoracic chemotherapy procedures by combining capital equipment with a proprietary pre-assembled "Hang & Go" disposable kit consumed per treatment. Technical components include dual high-flow roller pumps (up to 2 Lpm), an integrated weighing system for automatic fluid balance control, a high-efficiency plate warmer, temperature monitoring across up to 8 probes, automatic procedure phase activation via pinch-valves, an integrated UPS for treatment continuity during power failures, and USB data recording with proprietary Excel-based reporting software. The Performer system is reported as installed in more than 200 centers worldwide with over 20,000 treatments executed. RanD holds FDA clearance for Performer HT and operates a quality system compliant with 21 CFR 820, IEC 60601-1, IEC 60601-1-2, IEC 62304, and IEC 62366.

RanD operates a hybrid B2B go-to-market model combining direct sales and an expanding international distribution network, supplemented by participation in international medical congresses and ongoing physician and technician training. Revenue derives from capital equipment sales, recurring sales of proprietary disposable kits consumed per procedure, and after-sales service. The primary customer segment is acute care hospitals and specialized medical centers performing surgical oncology and other extracorporeal circulation therapies, with surgeons and oncologists as the principal physician users. A US subsidiary, RanD USA Inc. (originally established in Miami, FL in 2012 and now operating from Hoschton, Georgia), directly serves the North American market following FDA clearance, while European customers are served from the Italian headquarters.

Name

RanD

Legal name

RanD S.r.l

Website

https://rand-biotech.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

RanD S.p.A. is an Italian medical technology company that designs, manufactures, and distributes the Performer platform of extracorporeal circulation systems—led by the Performer HT hyperthermic perfusion system—for hospitals and surgical oncologists performing heated chemotherapy and related extracorporeal therapies worldwide.

Ownership category

akta.pro rank

Headquarters

HQ city

Medolla

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Medical Equipment Sales: Sale of capital medical equipment including Performer HT, Performer LRT, and Performer CPB systems to hospitals and medical centers worldwide for surgical oncology and extracorporeal circulation therapies.
2. Disposable Kit Sales: Recurring sales of Hang & Go pre-assembled disposable kits for the Performer HT system, which are consumed during each hyperthermic perfusion procedure.
3. After-Sales Service: Professional after-sales service provided through a globally trained distribution network to support installed base of medical equipment.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

The provided input contains no source-backed evidence describing RanD's core offerings. The only content provided is a reasoning block without any resolvable WX-prefixed source ID, so no factual extraction can be performed.

Product overview

RanD is a knowledge-based medical technology company established in 1999, specializing in the development and manufacturing of technologically innovative systems based on extracorporeal circulation technologies. The company manufactures both equipment and disposable devices primarily focused on surgical oncology. The product portfolio centers on the Performer platform, which includes Performer HT (hyperthermic perfusion system for surgical oncology), Performer LRT (multifunctional system for CRRT, Plasma Exchange, Artificial/Bio-Artificial Liver support, and Surgical oncology), and Performer CPB (heart-lung machine developed for Medtronic). RanD also established Rigenerand as a 2016 spin-off focused on regenerative medicine. The company operates from the Mirandola Bio-medical district in Italy and maintains a US presence through RanD USA.

Differentiator

Problem solved

Functional benefit

Brands

• Performer HT: The most advanced system for Hyperthermic Perfusion - dedicated system (equipment and disposable) for hyperthermic treatments in surgical oncology.
• Performer LRT
• Performer CPB

Quantifiable outcome

• Performer system deployed in over 200 centers worldwide with over 20,000 treatments executed

Segments2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Medtronic Inc.majorStrategic or Co-development Partner · 1 January 2005RanD developed the Performer CPB, the first high-rise heart-lung machine with one-third footprint of legacy systems, specifically for Medtronic Inc. This represents a significant co-development partnership where RanD applied its extracorporeal circulation expertise to create specialized cardiopulmonary bypass equipment for a major medical device company.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Belmont Medical Technologies: Specializes in fluid management and rapid infusion / hyperthermia systems for surgical and trauma settings. Comparable niche medical device vendor with overlapping customer base in hospitals and surgical suites, focused on perfusion-adjacent devices.
• Eurosets: Italian-headquartered medical device company specializing in extracorporeal circulation and perfusion systems, with overlapping products for cardiopulmonary bypass, ECMO, and oncology perfusion. Highly comparable to RanD on geography, technology base, and customer base (hospitals and cardiac/oncology surgeons).

Broad incumbents

• Smith+Nephew: Global medical device player with relevant surgical oncology and advanced wound management portfolios. Comparable hospital surgical buyer, less direct on extracorporeal perfusion technology.
• Getinge (Maquet): Getinge's Maquet business sells heart-lung machines, surgical perfusion disposables, and OR equipment worldwide. Directly comparable on cardiopulmonary bypass and perfusion equipment, with a much broader product portfolio.
• Terumo (Cardiovascular / Perfusion): Diversified Japanese medtech with a major cardiopulmonary and perfusion business (Terumo Cardiovascular). Overlaps with RanD on perfusion and oxygenator/disposable technology and competes for the same surgical hospital accounts.
• Stryker (Surgical Instruments): Large medtech incumbent with a Surgical Instruments and Oncology / Surgical Technologies portfolio serving the same hospital surgical oncology buyers. Comparable customer base and procedural overlap, though not direct competition in perfusion hardware.
• Medtronic: Global medtech giant and RanD's former OEM partner for Performer CPB. Comparable on cardiopulmonary bypass products and on broader surgical oncology portfolios, but at vastly greater scale and across many other therapy areas.
• Johnson & Johnson (Ethicon Surgical Oncology): Ethicon's surgical oncology and advanced energy devices compete in the same operating room and oncology hospital channels. Comparable end-customer (surgical oncology departments) but offers a much broader procedural portfolio.
• LivaNova (Cardiopulmonary / Perfusion): Global medtech incumbent in cardiopulmonary bypass and perfusion, including heart-lung machines and autotransfusion systems. Comparable to RanD on core technology (extracorporeal circulation) but operates at materially larger scale across many therapy lines.

Regional players

• Estor (Italy): Italy-based manufacturer of medical devices for perfusion and cardiac surgery, anchored in the same Mirandola biomedical cluster as RanD. Highly comparable on geography and product overlap, primarily serving European perfusion and cardiac surgery markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rand_spa

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RanD